• Third patient safely dosed with RC220 in the CPACS Phase 1 trial
• Recruitment completion enables initiation of the next dose level cohort
• Next cohort patients to be recruited from multiple sites in Australia, Hong Kong and South Korea

Racura Oncology Limited is pleased to announce the dosing of the third patient with RC220 in its CPACS Phase 1 clinical trial in advanced solid tumours at the first Hong Kong site. The patient was treated by Principal Investigator Dr Roland Ching-Yu Leung and his team at the Queen Mary Hospital. No phlebitis (vein inflammation) or any other adverse events were reported following dosing at 40mg/m2 of RC220. This follows successful first and second patient treatment at the Southside Cancer Care Centre. To date, no dose limiting toxicities have been observed in any patient in the study. Dosing of the third patient also completes recruitment of the first trial cohort. In accordance with the trial protocol, the Safety Review Committee (SRC) will review all accumulated safety data collected from the three patients. Subject to SRC review and clearance, the trial will then progress to the next planned RC220 dose level of 80 mg/m2 using the updated trial protocol announced 11 February 2026. Racura's Phase 1 solid tumour clinical trial is open-label and is being conducted across multiple sites in Australia, Hong Kong, and South Korea. Stage 1 of the trial is using ascending doses of RC220 to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose (MTCD) of RC220 in combination with doxorubicin in up to 33 patients. Effects on a range of clinical biomarkers, including a blood-based measure of the cardioprotective mechanism of action of RC220, will also be examined. After interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals.

Racura intends to announce progress updates on the trial on a regular basis, but not at the individual patient level.